A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Autor: O'Neil, B.H., Scott, A.J., Ma, W.W., Cohen, S.J., Aisner, D.L., Menter, A.R., Tejani, M.A., Cho, J.K., Granfortuna, J., Coveler, A.L., Olowokure, O.O., Baranda, J.C., Cusnir, M., Phillip, P., Boles, J., Nazemzadeh, R., Rarick, M., Cohen, D.J., Radford, J., Fehrenbacher, L., Bajaj, R., Bathini, V., Fanta, P., Berlin, J., McRee, A.J., Maguire, R., Wilhelm, F., Maniar, M., Jimeno, A., Gomes, C.L., Messersmith, W.A.
Zdroj: In Annals of Oncology June 2016 27(6):1180-1180
Databáze: ScienceDirect